RedHill Biopharma (RDHL) COO uses ADS sale to cover RSU taxes

Rhea-AI Filing Summary

RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported compensation-related share activity tied to restricted share unit vesting. A trustee sold 1,574 American Depositary Shares (ADS) solely to cover tax withholding, at $0.8001 per ADS, equal to 15,740,000 ordinary shares based on 10,000 ordinary shares per ADS. Following this sale, Raday’s direct holdings in ordinary shares were 261,060,000. He also exercised derivative rights over 30,780,000 ADS representing 30,780,000 underlying ordinary shares, leaving 76,150,000 ADS directly held. Footnotes state the transaction was executed under a sell-to-cover policy and did not represent a discretionary trade by Raday.

Insider Trade Summary

Net Seller: 15,740,000 shares ($1,574)

Net Sell 2 txns

Insider Raday Gilead

Role Chief Operating Officer

Sold 15,740,000 shs ($2K)

Type	Security	Shares	Price	Value
Exercise	American Depositary Shares	30,780,000	$0.00	--
Sale	Ordinary Shares	15,740,000	$0.0001	$2K

Holdings After Transaction: American Depositary Shares — 76,150,000 shares (Direct, null); Ordinary Shares — 261,060,000 shares (Direct, null)

Footnotes (1)

1. The reporting person sold 1,574 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,652 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person. The price reported in Table I Column 4 is $0.8001 per ADS, which would be equivalent to $0.00008001 per ordinary share. Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raday Gilead

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/06/2026		S(1)		15,740,000(1)	D	$0.0001(2)	261,060,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(3)	04/06/2026		M		30,780,000		(3)	(3)	Ordinary Shares	30,780,000	$0	76,150,000	D

Explanation of Responses:

1. The reporting person sold 1,574 American Depositary Shares ("ADS") of RedHill Biopharma Inc. (the "Issuer"), each ADS represents 10,000 ordinary shares, par value NIS 0.01 per share, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,652 restricted share units granted to him on July 1, 2023, June 24, 2024, March 26, 2025 and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.

2. The price reported in Table I Column 4 is $0.8001 per ADS, which would be equivalent to $0.00008001 per ordinary share.

3. Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.

	/s/ Gilead Raday	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)